# Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

> **NCT03011034** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 34 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Talacotuzumab
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03011034
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2019-01-23
- **Final completion:** 2021-10-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011034, "Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03011034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*